DiFazio L T, Stratoulias C, Greco R S, Haimovich B
Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, New Brunswick 08903-0019.
J Surg Res. 1994 Jul;57(1):133-7. doi: 10.1006/jsre.1994.1120.
The interactions between platelets and plasma proteins previously shown to adhere to biomaterials were evaluated, using monoclonal antibodies (mAbs) against specific platelet surface glycoprotein (GP) receptors. Purified 51Cr-labeled human platelets in plasma-free medium were incubated with each of the following antibodies: mAb 10E5 [anti-GP IIb/IIIa; fibrinogen, von Willebrand factor (vWF), and fibronectin receptor]; mAb 6D1 (anti-GP Ib-IX; vWF receptor); mAb IV.3 (anti-Fc gamma RII; IgG receptor); polyclonal antiserum A108 or mAb BIIG4 (anti-GP Ic-IIa; fibronectin receptor). Antibody-treated platelets were added to microtiter wells coated with fibronectin, fibrinogen, vWF, IgG, vitronectin, albumin, or platelet-poor plasma (PPP). 51Cr-labeled platelet adhesion to matrix proteins was expressed as a percentage of that measured on PPP-coated surface. Platelets adhered to fibrinogen, fibronectin, vWF, or IgG immobilized on polystyrene. Limited binding to either vitronectin or albumin was detected. Binding to fibrinogen and IgG was blocked by mAb 10E5. Binding to IgG was also blocked by mAb IV.3. Binding to fibronectin, reduced in the presence of mAb 10E5, mAb BIIG4, or the polyclonal antiserum A108 alone, was further reduced by combined 10E5 and BIIG4 or 10E5 and A108. Neither mAb 10E5 nor 6D1 alone blocked adhesion to vWF; however, the combination of 10E5 and 6D1 significantly reduced platelet adhesion to this matrix. Finally, platelet adhesion to the plasma-coated surface was reduced by mAbs 10E5 and BIIG4. These results indicate that multiple adhesion receptors can mediate platelet adhesion to matrix proteins immobilized on surfaces.
使用针对特定血小板表面糖蛋白（GP）受体的单克隆抗体（mAb），评估先前已证明可粘附于生物材料的血小板与血浆蛋白之间的相互作用。将无血浆培养基中纯化的51Cr标记的人血小板与以下每种抗体孵育：mAb 10E5 [抗GP IIb/IIIa；纤维蛋白原、血管性血友病因子（vWF）和纤连蛋白受体]；mAb 6D1（抗GP Ib-IX；vWF受体）；mAb IV.3（抗FcγRII；IgG受体）；多克隆抗血清A108或mAb BIIG4（抗GP Ic-IIa；纤连蛋白受体）。将经抗体处理的血小板添加到包被有纤连蛋白、纤维蛋白原、vWF、IgG、玻连蛋白、白蛋白或乏血小板血浆（PPP）的微量滴定孔中。51Cr标记的血小板对基质蛋白的粘附以在PPP包被表面上测得的粘附的百分比表示。血小板粘附于固定在聚苯乙烯上的纤维蛋白原、纤连蛋白、vWF或IgG。检测到与玻连蛋白或白蛋白的结合有限。mAb 10E5可阻断与纤维蛋白原和IgG的结合。mAb IV.3也可阻断与IgG的结合。在单独存在mAb 10E5、mAb BIIG4或多克隆抗血清A108的情况下，与纤连蛋白的结合减少，而10E5与BIIG4或10E5与A108联合使用可进一步减少结合。单独的mAb 10E5和6D1均未阻断对vWF的粘附；然而，10E5和6D1的组合可显著降低血小板对该基质的粘附。最后，mAb 10E5和BIIG4可降低血小板对血浆包被表面的粘附。这些结果表明，多种粘附受体可介导血小板对固定在表面上的基质蛋白的粘附。
